TY - JOUR
T1 - Eye Dynamics and Engineering Network Consortium
T2 - Baseline Characteristics of a Randomized Trial in Healthy Adults
AU - Reed, David M.
AU - Toris, Carol B.
AU - Gilbert, Jesse
AU - Trese, Matthew
AU - Kristoff, Tyler J.
AU - Fan, Shan
AU - Neely, Donna
AU - Ferguson, Simone
AU - Kazemi, Arash
AU - McLaren, Jay W.
AU - Gulati, Vikas
AU - Musch, David C.
AU - Sit, Arthur J.
AU - Moroi, Sayoko E.
N1 - Funding Information:
The authors made the following disclosures: C.B.T.: Support – Georgia The Foundation Grant, Novartis, Bright Focus Grant, R24EY029950-01 (Jablonski), Iantrek; Travel Expenses – International Society for Eye Research.M.T.: Consultant – Regenxbio; Expert Testimony – July 2022, personal injury case, fee donated to Pediatric Retinal Research Foundation; Leadership – Michigan Society of Eye Physicians and Surgeons.V.G.: Support – National Eye Institute K23EY023266.A.J.S.: Support – NIH/NEI R01EY22124 (PI – Moroi), Mayo Foundation for Medical Education and Research, Qlaris Bio, National Aeronautics and Space Administration; Consultant – Aerie Pharmaceuticals, Allergan, Bausch Health, Injectsense, PolyActiva, Qlaris Bio; Leadership – World Glaucoma Association; Shares – Injectsense.S.E.M: Support – P30EY007003 (University of Michigan), UL1TR000433 (University of Michigan), Research to Prevent Blindness (University of Michigan), U41HG007050 (PhenX Toolkit), Research to Prevent Blindness (Mayo Clinic); Honoraria, Travel Expenses – Wolters Kluwer Shields’ Textbook of Glaucoma, Columbia University Max Forbes MD lecture (5/12/22), 43th Annual Midwest Glaucoma Symposium (9/25–26/20), 2022 H. Saul Sugar Lecturer, Henry Ford Health System (5/7/22), 27th Annual Roger P. Mason, MD lecture, Howard University (9/11/20), Visiting Professor, Mount Sinai (5/13-14/21); Patents – US Patent #10575723.Funded by the National Eye Institute (NEI) EY022124. Additional support from Research to Prevent Blindness Unrestricted Grant (University of Michigan; Mayo Clinic), from the Core Center for Vision Research (P30 EY007003), from the Michigan Institute for Clinical & Health Research for support with the Research Electronic Data Capture database (CTSA: UL1TR000433). PhenX is funded by the National Institutes of Health (NIH) Genomic Resource Grant (U41HG007050) from the National Human Genome Research Institute (NHGRI) with current or prior funding support from the National Institute on Drug Abuse (NIDA), Office of Behavioral and Social Sciences Research (OBSSR), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Minority Health and Health Disparities (NIMHD) and Tobacco Regulatory Science Program (TRSP). The sponsor or funding organization had no role in the design or conduct of this research. Obtained funding: Moroi
Funding Information:
The authors made the following disclosures: C.B.T.: Support – Georgia The Foundation Grant, Novartis , Bright Focus Grant, R24EY029950-01 (Jablonski), Iantrek; Travel Expenses – International Society for Eye Research .
Funding Information:
Funded by the National Eye Institute (NEI) EY022124. Additional support from Research to Prevent Blindness Unrestricted Grant (University of Michigan; Mayo Clinic ), from the Core Center for Vision Research (P30 EY007003), from the Michigan Institute for Clinical & Health Research for support with the Research Electronic Data Capture database (CTSA: UL1TR000433). PhenX is funded by the National Institutes of Health (NIH) Genomic Resource Grant (U41HG007050) from the National Human Genome Research Institute (NHGRI) with current or prior funding support from the National Institute on Drug Abuse (NIDA), Office of Behavioral and Social Sciences Research (OBSSR), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Minority Health and Health Disparities (NIMHD) and Tobacco Regulatory Science Program (TRSP). The sponsor or funding organization had no role in the design or conduct of this research.
Publisher Copyright:
© 2022 American Academy of Ophthalmology
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Purpose: To improve understanding of intraocular pressure (IOP) and its variance, this project identifies systemic and ocular characteristics of healthy eyes of adult volunteers including IOP variation, ocular biometrics, and aqueous humor dynamics (AHDs). These data serve as baseline controls for further studies from the Eye Dynamics and Engineering Network (EDEN) Consortium. Design: Multicenter open-label clinical trial in healthy adults randomized to 1 week treatment with 2 approved glaucoma drugs in a crossover design. Participants: Among 135 healthy participants, 122 participants (aged 55.2 ± 8.8 years; 92 females, 30 males) completed the protocol. Methods: Participants from the University of Michigan, Mayo Clinic, and University of Nebraska Medical Center underwent measurements of ocular biometrics, AHD, and IOP using 4 tonometers. Intraocular pressure data during 3 study visits without glaucoma medications were used in the analysis. The PhenX Toolkit survey acquired standardized data on medical history, surgical history, medications, smoking and alcohol exposures, and physical measures. Main Outcome Measures: The variability of IOP measurements within eyes was assessed as visit-to-visit IOP variation, within-visit IOP variation, and within-visit positional IOP variation. The concordance (or correlation) between eyes was also assessed. Results: Average positional change of > 4.7 mmHg was detected with a range of 0.5–11.0 mmHg. Pearson correlation of IOP between eyes within a visit was 0.87 (95% confidence interval [CI], 0.82–0.91) for Goldmann applanation tonometry, 0.91 (95% CI, 0.88–0.94) for Icare rebound tonometry, and 0.91 (95% CI, 0.88–0.94) for pneumatonometry. There was a 4% to 12% asymmetric fluctuation of 3 mmHg or more between eyes between visits using rebound tonometry, 9% with Goldmann applanation tonometry, and 3% to 4% by pneumotonometry. The coefficient of variation between visits for the same eye ranged from 11.2% to 12.9% for pneumatonometry, from 13.6% to 17.4% for rebound tonometry, and 15.8% to 16.2% for Goldmann applanation tonometry. Conclusions: The current study from the EDEN Consortium describes measurement methods and data analyses with emphasis on IOP variability. Future papers will focus on changes in ocular biometrics and AHD with timolol or latanoprost treatment. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
AB - Purpose: To improve understanding of intraocular pressure (IOP) and its variance, this project identifies systemic and ocular characteristics of healthy eyes of adult volunteers including IOP variation, ocular biometrics, and aqueous humor dynamics (AHDs). These data serve as baseline controls for further studies from the Eye Dynamics and Engineering Network (EDEN) Consortium. Design: Multicenter open-label clinical trial in healthy adults randomized to 1 week treatment with 2 approved glaucoma drugs in a crossover design. Participants: Among 135 healthy participants, 122 participants (aged 55.2 ± 8.8 years; 92 females, 30 males) completed the protocol. Methods: Participants from the University of Michigan, Mayo Clinic, and University of Nebraska Medical Center underwent measurements of ocular biometrics, AHD, and IOP using 4 tonometers. Intraocular pressure data during 3 study visits without glaucoma medications were used in the analysis. The PhenX Toolkit survey acquired standardized data on medical history, surgical history, medications, smoking and alcohol exposures, and physical measures. Main Outcome Measures: The variability of IOP measurements within eyes was assessed as visit-to-visit IOP variation, within-visit IOP variation, and within-visit positional IOP variation. The concordance (or correlation) between eyes was also assessed. Results: Average positional change of > 4.7 mmHg was detected with a range of 0.5–11.0 mmHg. Pearson correlation of IOP between eyes within a visit was 0.87 (95% confidence interval [CI], 0.82–0.91) for Goldmann applanation tonometry, 0.91 (95% CI, 0.88–0.94) for Icare rebound tonometry, and 0.91 (95% CI, 0.88–0.94) for pneumatonometry. There was a 4% to 12% asymmetric fluctuation of 3 mmHg or more between eyes between visits using rebound tonometry, 9% with Goldmann applanation tonometry, and 3% to 4% by pneumotonometry. The coefficient of variation between visits for the same eye ranged from 11.2% to 12.9% for pneumatonometry, from 13.6% to 17.4% for rebound tonometry, and 15.8% to 16.2% for Goldmann applanation tonometry. Conclusions: The current study from the EDEN Consortium describes measurement methods and data analyses with emphasis on IOP variability. Future papers will focus on changes in ocular biometrics and AHD with timolol or latanoprost treatment. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
KW - Aqueous humor dynamics, Glaucoma, Intraocular pressure, IOP
UR - http://www.scopus.com/inward/record.url?scp=85140732410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140732410&partnerID=8YFLogxK
U2 - 10.1016/j.ogla.2022.09.001
DO - 10.1016/j.ogla.2022.09.001
M3 - Article
C2 - 36096354
AN - SCOPUS:85140732410
SN - 2589-4234
VL - 6
SP - 215
EP - 223
JO - Ophthalmology. Glaucoma
JF - Ophthalmology. Glaucoma
IS - 2
ER -